Tumor vaccine against recurrence of hepatocellular carcinoma

Table 1 Base-line data of vaccinated and control patients (mean±SD).

	Vaccinated (n = 24, %)	Control (n = 26, %)
Age (yr)	53±9	49±15
Male	22 (92)	21 (81)
Female	2 (8)	5 (19)
Cause of liver injury
Hepatitis B	19 (79.1)	18 (69.2)
Hepatitis C	1 (4.2)	2 (7.7)
Unknown	4 (16.7)	6 (23.1)
Child-Pugh class A	23 (96)	24 (92)
Child-Pugh class B	1 (4)	2 (8)
Alanine aminotransferase (U/L)	75±35	50±95
Cirrhosis	16 (67)	16 (62)
a-fetoprotein
≥400 mg/L	17 (71.3)	16 (61.5)
<400 mg/L	7 (28.7)	10 (38.5)
Tumor size (major axis, mm)	63±22	56±36
AJCC stage I	4 (17)	2 (8)
AJCC stage II	20 (83)	24 (92)
Style of operation
Left lateral lobectomy	3	4
Left hepatectomy	8	5
Right hepatectomy	2	3
Irregular hepatectomy	11	14
Blood loss during operation (mL)	812±536	769±620
Blood transfusion during operation (mL)	542±521	638±612

Table 2 Surface phenotypes of peripheral blood lymphocytes (mean±SD).

	Control (n=26)	Before vaccination (n=24)	After vaccination (n=24)
CD3+	73.5±5.8	70.4±7.2	71.9±6.5
CD3+CD4+	45.2±9.7	48.3±7.6	49.0±9.2
CD3+CD8+	29.3±9.8a	27.9±7.5a	39.9±10.5a
CD4+/CD8+	2.02±0.39c	2.15±0.98c	1.03±1.13c
CD3-CD16+56+	18.5±3.9	16.9±8.3	19.7±9.3

^aP<0.05,

^cP<0.05 after tumor vaccination vs control or before tumor vaccination.